248 related articles for article (PubMed ID: 21590629)
1. [Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)].
Datz N; Nestoris C; von Schütz W; Danne T; Driesel AJ; Maringa M; Kordonouri O
Dtsch Med Wochenschr; 2011 May; 136(21):1111-5. PubMed ID: 21590629
[TBL] [Abstract][Full Text] [Related]
2. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
[TBL] [Abstract][Full Text] [Related]
3. Onset of type 1 diabetes mellitus in two patients with maturity onset diabetes of the young.
Maltoni G; Zucchini S; Scipione M; Mantovani V; Salardi S; Cicognani A
Pediatr Diabetes; 2012 Mar; 13(2):208-12. PubMed ID: 21696527
[TBL] [Abstract][Full Text] [Related]
4. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
[TBL] [Abstract][Full Text] [Related]
5. Mutation screening in 18 Caucasian families suggest the existence of other MODY genes.
Chèvre JC; Hani EH; Boutin P; Vaxillaire M; Blanché H; Vionnet N; Pardini VC; Timsit J; Larger E; Charpentier G; Beckers D; Maes M; Bellanné-Chantelot C; Velho G; Froguel P
Diabetologia; 1998 Sep; 41(9):1017-23. PubMed ID: 9754819
[TBL] [Abstract][Full Text] [Related]
6. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.
Estalella I; Rica I; Perez de Nanclares G; Bilbao JR; Vazquez JA; San Pedro JI; Busturia MA; Castaño L;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):538-46. PubMed ID: 17573900
[TBL] [Abstract][Full Text] [Related]
7. Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.
Warncke K; Kummer S; Raile K; Grulich-Henn J; Woelfle J; Steichen E; Prinz N; Holl RW
J Clin Endocrinol Metab; 2019 Mar; 104(3):845-855. PubMed ID: 30535056
[TBL] [Abstract][Full Text] [Related]
8. Genetic and clinical characteristics of Korean maturity-onset diabetes of the young (MODY) patients.
Hwang JS; Shin CH; Yang SW; Jung SY; Huh N
Diabetes Res Clin Pract; 2006 Oct; 74(1):75-81. PubMed ID: 16632067
[TBL] [Abstract][Full Text] [Related]
9. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
Pihoker C; Gilliam LK; Ellard S; Dabelea D; Davis C; Dolan LM; Greenbaum CJ; Imperatore G; Lawrence JM; Marcovina SM; Mayer-Davis E; Rodriguez BL; Steck AK; Williams DE; Hattersley AT;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4055-62. PubMed ID: 23771925
[TBL] [Abstract][Full Text] [Related]
11. The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young.
Bacon S; Schmid J; McCarthy A; Edwards J; Fleming A; Kinsley B; Firth R; Byrne B; Gavin C; Byrne MM
Am J Obstet Gynecol; 2015 Aug; 213(2):236.e1-7. PubMed ID: 25935773
[TBL] [Abstract][Full Text] [Related]
12. Clinical profiling and screening for HNF4α and GCK gene mutations in Kashmiri patients with maturity-onset diabetes of the young (MODY).
Firdous P; Hassan T; Nissar K; Masoodi SR; Ganai BA
Prim Care Diabetes; 2022 Apr; 16(2):325-332. PubMed ID: 35131168
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the genes for hepatocyte nuclear factor (HNF)-1alpha, -4alpha, -1beta, and -3beta; the dimerization cofactor of HNF-1; and insulin promoter factor 1 are not common causes of early-onset type 2 diabetes in Pima Indians.
Baier LJ; Permana PA; Traurig M; Dobberfuhl A; Wiedrich C; Sutherland J; Thuillez P; Luczy-Bachman G; Hara M; Horikawa Y; Hinokio Y; Hanson RL; Bogardus C
Diabetes Care; 2000 Mar; 23(3):302-4. PubMed ID: 10868855
[TBL] [Abstract][Full Text] [Related]
14. Response to oral gliclazide in a pre-pubertal child with hepatic nuclear factor-1 alpha maturity onset diabetes of the young.
Habeb AM; George ET; Mathew V; Hattersley AL
Ann Saudi Med; 2011; 31(2):190-3. PubMed ID: 21242637
[TBL] [Abstract][Full Text] [Related]
15. RD Lawrence lecture 2012: assessing aetiology in diabetes: how C-peptide, CRP and fucosylation came to the party!
Owen KR
Diabet Med; 2013 Mar; 30(3):260-6. PubMed ID: 23106207
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of maturity onset-diabetes of the young caused by hepatocyte nuclear factor-4 alpha mutation: red flags for prediction of the diagnosis.
Mohamed S; Elkholy S; El-Meleagy E; Abu-Amero K; Hellani AM
Ann Saudi Med; 2014; 34(3):217-21. PubMed ID: 25266181
[TBL] [Abstract][Full Text] [Related]
17. Maturity-onset diabetes of the young (MODY): a new challenge for pediatric diabetologists.
Guazzarotti L; Bartolotta E; Chiarelli F
J Pediatr Endocrinol Metab; 1999; 12(4):487-97. PubMed ID: 10417964
[TBL] [Abstract][Full Text] [Related]
18. Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha.
Pruhova S; Ek J; Lebl J; Sumnik Z; Saudek F; Andel M; Pedersen O; Hansen T
Diabetologia; 2003 Feb; 46(2):291-5. PubMed ID: 12627330
[TBL] [Abstract][Full Text] [Related]
19. Different genes, different diabetes: lessons from maturity-onset diabetes of the young.
Stride A; Hattersley AT
Ann Med; 2002; 34(3):207-16. PubMed ID: 12173691
[TBL] [Abstract][Full Text] [Related]
20. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
